Evaluation of the impact of previously resolved early aGVHD on immune profiles at day 100 in patients who will develop late aGVHD or cGVHD. Volcano plots showing significant markers that meet all 3 criteria: P ≤ .05 (y-axis), ROC AUC ≥0.60 (circle, ≥0.60; cross, <0.6), and effect ratio ≥1.3 or ≤0.75 (x-axis). The subfigures correspond to (A) active late aGVHD compared with tolerant patients, (B) late aGVHD compared with patients who has clearly resolved aGVHD, (C) cGVHD compared with tolerant patients, and (D) cGVHD compared with patients with previous resolved early aGVHD. Cell population are identified by color, with dark blue representing B cells, orange myeloid populations, yellow NK cells, purple NK_reg cells, green T cells, light blue T_reg cells, and dark red plasma cytokines. We note the following clinical variables were modeled as confounding factors in the logistic regression model: (1) prophylaxis or treatment with either alemtuzumab or ATG, (2) prophylaxis or treatment with rituximab, (3) recipient age, (4) the use of a peripheral blood donor product or not, and (5) whether the donor was HLA-identical or not.